LDN-193189 (dihydrochloride)


CAS No. : 1435934-00-1

(Synonyms: DM-3189 (dihydrochloride))

1435934-00-1
Price and Availability of CAS No. : 1435934-00-1
Size Price Stock
5mg $84 In-stock
10mg $108 In-stock
25mg $195 In-stock
50mg $288 In-stock
100mg $425 In-stock
200mg $616 In-stock
500mg $1080 In-stock
1 g Get quote
5 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-12071B
M.Wt: 479.40
Formula: C25H24Cl2N6
Purity: >98 %
Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C);H2O : 11.11 mg/mL (ultrasonic)
Introduction of 1435934-00-1 :

LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3]. In Vitro: LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively[1].
LDN-193189 has weake effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7 with IC50 values of ≥ 500 nM[1].
LDN-193189 binds ActRIIA with Kd value of 14 nM[2].
LDN-193189 (0.5 μM; 30 min) targets GDF8 induced Smad2/3 signaling and repression of myogenic transcription factors[2].
LDN-193189 (0.05, 0.5, 5 μM) efficiently inhibits GDF8 induced Smad3/4 reporter gene activity[2].
LDN-193189 (0-5 μM) rescues myogenesis in myoblasts treated with GDF8[2]. In Vivo: LDN-193189 (i.p.; 3 mg/kg; daily; for 35 days) might affect the interaction between breast cancer cells and the bone environment[3].
LDN-193189 (i.p.; 3 mg/kg; single) shows a reduction in ectopic ossification and functional impairment[1].

Your information is safe with us.